Ann Richmond
Affiliations: | Vanderbilt University, Nashville, TN |
Area:
Cell BiologyGoogle:
"Ann Richmond"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bullock K, Richmond A. (2021) Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy. Cancers. 13 |
| Richmond A, Yang J, Yan C, et al. (2020) Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity. Cancer Immunology Research |
| Vilgelm AE, Bergdorf K, Wolf M, et al. (2020) Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. Iscience. 23: 101408 |
| Williams CB, Nebhan CA, Yang J, et al. (2020) Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. Breast Cancer Research and Treatment |
| Shattuck-Brandt RL, Chen SC, Murray E, et al. (2020) Metastatic Melanoma Patient-derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Bharti V, Blevins A, Weiss VL, et al. (2020) Abstract B20: Patient-derived organoids demonstrate synergistic effect of co-targeting Aurora kinase and prosurvival BCL2 family proteins Cancer Research. 80 |
| Vilgelm AE, Saleh N, Shattuck-Brandt R, et al. (2019) MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Science Translational Medicine. 11 |
| Vilgelm AE, Richmond A. (2019) Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Frontiers in Immunology. 10: 333 |
| Blevins A, Mont S, Lawrence H, et al. (2019) Abstract 2552: Senescence induced by CDK4/6 inhibition facilitates anti-tumor T cell responses Cancer Research |
| Yan C, Reddy PE, Richmond A. (2019) Abstract 3201: Rigosertib, a Ras mimetic, inhibits melanoma cell viability and synergizes with anti-PD1 to promote anti-tumor immune responses Cancer Research. 79: 3201-3201 |